Uncategorized
ENIXYTIL Trademark Filings Advance Proprietary Caffeine Technology for Modern Oral Delivery
denmarkENIXYTIL is a proprietary modified caffeine technology developed by N.G.P. Tobacco ApS for modern oral delivery systems and the company’s next generation of Performance Pouches.
ENIXYTIL is a proprietary modified caffeine technology developed by N.G.P. Tobacco ApS for modern oral delivery systems and the company’s next generation of Performance Pouches.
denmark
ENIXYTIL is a proprietary modified caffeine technology developed by N.G.P. Tobacco ApS for modern oral delivery systems and the company’s next generation of Performance Pouches.
ENIXYTIL is an innovative modified form of anhydrous caffeine developed specifically for modern oral delivery systems. Unlike conventional caffeine formats designed primarily to be swallowed, ENIXYTIL is intended for products in which caffeine is first released within the oral cavity.
According to N.G.P. Tobacco ApS, the technology has modified physicochemical characteristics intended to support rapid dissolution in saliva, distribution across the oral mucosa and compatibility with modern oral product formats. The development approach is intended to preserve caffeine’s fundamental mechanism of action while adapting how caffeine can be formulated and delivered.
ENIXYTIL was developed through ongoing laboratory investigation, formulation research and product development. The company says the technology was engineered specifically for modern oral delivery systems and serves as the technological foundation for its next generation of Performance Pouches.
The ENIXYTIL trademark application was filed in the European Union on July 23, 2026 under application number 019399490 and published on August 11, 2026. Applications have also been filed in the United Kingdom and United States, giving ENIXYTIL a consistent standalone identity as the technology moves into further industry presentation and development.
The company is expanding public information around ENIXYTIL so industry partners and other stakeholders can clearly identify what the technology is, who developed it and the product formats for which it was created.
More information about ENIXYTIL, its development background and intended role in modern oral delivery systems is available at https://ngpeurope.eu/ngp-enixytil/
About N.G.P. Tobacco ApS
N.G.P. Tobacco ApS develops technologies and products for modern oral delivery systems through laboratory investigation, formulation research and continuous product development. ENIXYTIL is the company’s proprietary modified caffeine technology developed for modern oral delivery formats. More information is available at https://ngpeurope.eu/
Media Contact Details
Michael Peers
BrandVirality
Phone: 13022615308
Website: getbrandvirality.com